midostaurin: Clinical Trials

20 trials of midostaurin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 2 recruiting, 2 terminated, 2 withdrawn. 20 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 120Completed 12, Recruiting 2, Terminated 2, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1
Phase 28Completed 3, Withdrawn 2, Not yet recruiting 1, Recruiting 1, Terminated 1

Follow midostaurin: new trials by email Literature Review of midostaurin trials Research Report on midostaurin

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia
Venetoclax in association with 3+7 and midostaurin - Leukemia, Myeloid, Acute
Phase 1 / Phase 2Not yet recruitingUniversity Hospital, Bordeaux412026-09-012026-07-24
Revumenib in Combination With 7+3 + Midostaurin in AML
Revumenib, Midostaurin, Cytarabine - Acute Myeloid Leukemia, AML, Adult
Phase 1RecruitingRichard Stone, MD222024-12-062026-03-25
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
CPX-351, Midostaurin, Busulfan - Acute Myeloid Leukemia
Phase 1 / Phase 2WithdrawnGuenther Koehne2022-07-052024-10-01
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO - Acute Myeloid Leukemia
Phase 1 / Phase 2RecruitingTechnische Universität Dresden2142020-09-042025-09-08
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.
HDM201, Midostaurin - AML, Adult
Phase 1TerminatedInsel Gruppe AG, University Hospital Bern22020-07-132022-10-06
A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
CPX-351, Venetoclax, Midostaurin - Acute Myeloid Leukemia
Phase 1CompletedJazz Pharmaceuticals572019-12-022023-10-16
HDM201 Added to CT in R/R or Newly Diagnosed AML
HDM201, cytarabine, anthracycline - Leukemia, Myeloid, Acute
Phase 1 / Phase 2WithdrawnNovartis Pharmaceuticals2019-11-152020-01-09
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride - Acute Myeloid Leukemia
Phase 1CompletedUma Borate212019-03-132026-05-15
A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
LGH447, LGH447 + midostaurin - AML and High Risk MDS
Phase 1CompletedNovartis Pharmaceuticals702014-03-202020-12-17
Midostaurin (PKC412) for Locally Advanced Rectal Cancer
Midostaurin - Adenocarcinoma of the Rectum
Phase 1CompletedMassachusetts General Hospital192011-08-012018-12-12
PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Midostaurin - Hepatic Impairment
Phase 1CompletedNovartis Pharmaceuticals432011-03-072021-05-12
PKC412 and 5-Azacytidine
5-azacytidine, PKC412 - Leukemia
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center542011-03-012018-10-16
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
Granulocyte colony-stimulating factor (G-CSF), Cladribine, Cytarabine - Leukemia, Myeloid, Acute
Phase 1CompletedWashington University School of Medicine112010-11-012013-07-23
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
midostaurin, Bortezomib, mitoxantrone hydrochloride - Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following
Phase 1CompletedAlison Walker342010-08-012016-07-06
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia
combination therapy using decitabine and midostaurin - Acute Myeloid Leukemia
Phase 1CompletedUniversity of Kansas162010-03-012013-03-26
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
midostaurin - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals222009-09-012015-12-22
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia
midostaurin, azacitidine, bone marrow aspiration - Untreated Adult Acute Myeloid Leukemia
Phase 1 / Phase 2CompletedBrenda Cooper, MD342009-07-012022-06-30
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
RAD001, PKC412 - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 1Active not recruitingRichard Stone, MD292009-01-012026-03-25
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
cytarabine, daunorubicin hydrochloride, midostaurin - Acute Myeloid Leukemia (AML)
Phase 1CompletedNovartis Pharmaceuticals692004-02-012020-12-19
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)
Itraconazole, PKC412 - Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals1442002-01-302017-08-11

Conditions studied

Leukemia, Myeloid, Acute (17)  ·  Myelodysplastic Syndromes (5)  ·  Congenital Abnormalities (2)  ·  Leukemia (2)  ·  Neoplasm, Residual (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Rectal Neoplasms (1)

Sponsors

Novartis Pharmaceuticals (6)  ·  Richard Stone, MD (2)  ·  Alison Walker (1)  ·  Brenda Cooper, MD (1)  ·  Guenther Koehne (1)  ·  Insel Gruppe AG, University Hospital Bern (1)  ·  Jazz Pharmaceuticals (1)  ·  M.D. Anderson Cancer Center (1)  ·  Massachusetts General Hospital (1)  ·  Technische Universität Dresden (1)  ·  Uma Borate (1)  ·  University Hospital, Bordeaux (1)  ·  University of Kansas (1)  ·  Washington University School of Medicine (1)

Countries

United States (16)  ·  Germany (4)  ·  France (3)  ·  Italy (2)  ·  Netherlands (2)  ·  Australia (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Japan (1)  ·  Lithuania (1)  ·  Romania (1)  ·  Sweden (1)  ·  Switzerland (1)

Top investigators

Richard Stone, MD (2)  ·  Alison Walker, MD (1)  ·  Brenda Cooper, MD (1)  ·  Camille Abboud, M.D. (1)  ·  Casey Williams, PharmD (1)  ·  Guenther Koehne, MD. PhD (1)  ·  Jorge Cortes, MD (1)  ·  Theodore S Hong, MD (1)  ·  Thomas Pabst, Prof (1)  ·  Uma Borate, M.D. (1)

Results publications

PMID 22627678, PMID 24488798, PMID 26784138, PMID 40932876, PMID 41488889

NIH funding

2008 (1), 2018 (1)